Molecular targeted therapies for pancreatic cancer

American Journal of Surgery

Volumn 196, Issue 3, 2008, Pages 430-441

  Borja Cacho, Daniel ^a   Jensen, Eric Hans ^a   Saluja, Ashok Kumar ^a   Buchsbaum, Donald J ^b   Vickers, Selwyn Maurice ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

Death receptor; Epidermal growth factor receptor; Molecular targeted therapy; Pancreatic cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; MATUZUMAB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TOPOTECAN; VATALANIB;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; HUMAN; MEDLINE; MOLECULAR THERAPY; MUTATION; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MUTATION; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 49349104165     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2008.04.009     Document Type: Review

References (88)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Messick C., Hardacre J.M., McGee M.F., et al. Early experience with intraoperative radiotherapy in patients with resected pancreatic adenocarcinoma. Am J Surg 195 (2008) 308-312
3. Krempien R., Muenter M.W., Huber P.E., et al. Randomized phase II study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer-PARC: study protocol [ISRCTN56652283]. BMC Cancer 5 (2005) 131
4. Baxter N., Whitson B.A., and Tuttle T.M. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol 14 (2007) 1320-1326
5. Cowgill S.M., and Muscarella P. The genetics of pancreatic cancer. Am J Surg 186 (2003) 279-286
6. Muller M.W., Friess H., Köninger J., et al. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg 195 (2008) 221-228
7. Han S.S., Jang J.Y., Kim S.W., et al. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32 (2006) 271-275
8. Ishikawa O., Ohigashi H., Imaoka S., et al. Regional chemotherapy to prevent hepatic metastasis after resection of pancreatic cancer. Hepatogastroenterology 44 (1997) 1541-1546
9. Riall T.S., Nealon W.H., Goodwin J.S., et al. Pancreatic cancer in the general population: improvements in survival over the last decade. J Gastrointest Surg 10 (2006) 1212-1224
10. Eloubeidi M.A., Desmond R.A., Wilcox C.M., et al. Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg 192 (2006) 322-329
11. Riall T.S., Cameron J.L., Killemoe K.D., et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery 140 (2006) 764-772
12. Shaib Y.H., Davila J.A., and El-Serag H.B. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 24 (2006) 87-94
13. Postier R.G. The challenge of pancreatic cancer. Am J Surg 186 (2003) 579-582
14. Bilimoria K.Y., Bentrem D.J., Tomlinson J.S., et al. Quality of pancreatic cancer care at Veterans Administration compared with non-Veterans Administration hospitals. Am J Surg 194 (2007) 588-593
15. Zhang Y., Banerjee S., Wang Z., et al. Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. Cancer Res 66 (2006) 1025-1032
16. Talar-Wojnarowska R., and Malecka-Panas E. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit 12 (2006) 186-193
17. Arnoletti J.P., Buchsbaum D.J., Huang Z.Q., et al. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J Gastrointest Surg 8 (2004) 960-970
18. Kimura K., Sawada T., Komatsu M., et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 12 (2006) 4925-4932
19. Zhang H., Sawada T., Komatsu M., et al. Epidermal growth factor promotes invasiveness of pancreatic cancer cells through NF-kappaB-mediated proteinase productions. Pancreas 32 (2006) 101-109
20. Pino M.S., Shrader M., Baker C.H., et al. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res 66 (2006) 3802-3812
21. Bowers G., Reardon D., Hewitt T., et al. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 20 (2001) 1388-1397
22. Friess H., Yamanaka Y., Kobrin M.S., et al. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1 (1995) 1413-1420
23. Thybusch-Bernhardt A., Beckmann S., and Juhl H. Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. Int J Surg Invest 2 (2001) 393-400
24. Bianco C., Giovannetti E., Ciardiello F., et al. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 12 (2006) 7099-7107
25. Durkin A.J., Bloomston P.M., Rosemury A.S., et al. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg 186 (2003) 431-436
26. Korc M. Pancreatic cancer-associated stroma production. Am J Surg 194 suppl (2007) S84-S86
27. Scaltriti M., and Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12 (2006) 5268-5272
28. MacKenzie M.J. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 5 (2004) 541-549
29. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
30. El-Rayes B.F., Ali S., Ali I.F., et al. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res 66 (2006) 10553-10559
31. Wang Z., Sengupta R., Banerjee S., et al. Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res 66 (2006) 7653-7660
32. Xie K., Wei D., and Huag S. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev 17 (2006) 147-156
33. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22 (2004) 69-76
34. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
35. Overholser J.P., Prewett M.C., Hooper A.T., et al. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89 (2000) 74-82
36. Baumann M., and Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72 (2004) 257-266
37. Xiong H.Q., Rosenberg A., LoBuglio A., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 22 (2004) 2610-2616
38. Cohenuram M., and Saif M.W. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP 8 (2007) 4-15
39. Ono M., and Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12 (2006) 7242-7251
40. Ali S., El-Rayes B.F., Sarkar F.H., et al. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 4 (2005) 1943-1951
41. Socinski M.A. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res 13 suppl (2007) S4597-S4601
42. Vanhoefer U., Tewes M., Rojo F., et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22 (2004) 175-184
43. Graeven U., Kremer B., Sudhoff T., et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 94 (2006) 1293-1299
44. Sequist L.V. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 12 (2007) 325-330
45. Maurel J., Martin-Richard M., Conill C., et al. Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 66 (2006) 1391-1398
46. Czito B.G., Willett C.G., Bendell J.C., et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 24 (2006) 656-662
47. Ng S.S., Taso M.S., Nicklee T., et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 1 (2002) 777-783
48. Dragovich T., Huberman M., Von Hoff D.D., et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol 60 (2007) 295-303
49. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
50. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
51. Kwak E.L., Jankowsi J., Thayer S.P., et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12 (2006) 4283-4287
52. Rosetti M., Tesei A., Ulivi P., et al. Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. Cancer Biol Ther 4 (2005) 1089-1095
53. Tzeng C.W., Frolov A., and Frolova N. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 141 (2007) 464-469
54. Hamilton M., Wolf J.L., Rusk J., et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 12 (2006) 2166-2171
55. Buck E., Eyzaguirre A., Haley J.D., et al. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 5 (2006) 2051-2059
56. Saif M.W. Anti-angiogenesis therapy in pancreatic carcinoma. JOP 7 (2006) 163-173
57. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5 (2007) 203-220
58. Seo Y., Baba H., Fukuda T., et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88 (2000) 2239-2245
59. Niedergethmann M., Hildenbrand R., Wostbrock B., et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25 (2002) 122-129
60. Holloway S.E., Beck A.W., Shivakumar L., et al. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. Ann Surg Oncol 13 (2006) 1145-1155
61. Tang R.F., Wang S.X., Peng L., et al. Expression of vascular endothelial growth factors A and C in human pancreatic cancer. World J Gastroenterol 12 (2006) 280-286
62. Kurahara H., Takao S., Maemura K., et al. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin Cancer Res 10 (2004) 8413-8420
63. Cohen M.H., Gootenberg J., Keegan P., et al. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12 (2007) 356-361
64. De Gramont A., and Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 69 (2005) 46-56
65. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 (2005) 8033-8040
66. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 (2006) 1145-1151
67. Saito Y., Sunamura M., Motoi F., et al. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Cancer Gene Ther 13 (2006) 242-252
68. Hotz H.G., Hines O.J., Masood R., et al. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery 137 (2005) 192-199
69. Baker C.H., Solorzano C.C., and Fidler I.J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62 (2002) 1996-2003
70. Siu L.L., Awada A., Takimoto C.H., et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12 (2006) 144-151
71. Jia Z., Zhang J., Wei D., et al. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res 67 (2007) 4878-4885
72. Li L., Aggarwal B.B., Shishodia S., et al. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101 (2004) 2351-2362
73. Kunnumakkara A.B., Guha S., Krishnan S., et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67 (2007) 3853-3861
74. Aghdassi A., Phillips P., Dudeja V., et al. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res 67 (2007) 616-625
75. Debatin K.M., and Krammer P.H. Death receptors in chemotherapy and cancer. Oncogene 23 (2004) 2950-2966
76. Huerta S., Goulet E.J., and Livingston E.H. Colon cancer and apoptosis. Am J Surg 191 (2006) 517-526
77. Fulda S., Meyer E., Friesen C., et al. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 20 (2001) 1063-1075
78. Ghobrial I.M., Witzig T.E., and Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55 (2005) 178-194
79. Ashkenazi A., Pai R.C., Fong S., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104 (1999) 155-162
80. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
81. Cretney E., Takeda K., and Smyth M.J. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 39 (2007) 280-286
82. Ichikawa K., Liud W., Zhao L., et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7 (2001) 954-960
83. Vogler M., Durr K., Jovanovic M., et al. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 26 (2007) 248-257
84. Khanbolooki S., Nawrocki S.T., Arumugam T., et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 5 (2006) 2251-2260
85. Srivastava R.K. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3 (2001) 535-546
86. Fanale M.A., and Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67 (2007) 333-350
87. Tolcher A.W., Mita M., Meropol N.J., et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25 (2007) 1390-1395
88. DeRosier L.C., Huang Z.Q., Sellers J.C., et al. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb decreases pancreatic adenocarcinoma cell viability in vitro and growth in vivo. J Gastrointest Surg 10 (2006) 1291-1300